{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:04:07Z","timestamp":1792415047685,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12325-022-02129-x","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T16:02:44Z","timestamp":1653148964000},"page":"3248-3261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Na\u00efve Neovascular AMD"],"prefix":"10.1007","volume":"39","author":[{"given":"Angelo Maria","family":"Minnella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-1611","authenticated-orcid":false,"given":"Chiara","family":"Centini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gambini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pagliei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Falsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ciasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maceroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","unstructured":"Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila). 2017. https:\/\/doi.org\/10.22608\/apo.2017251.","DOI":"10.22608\/apo.2017251"},{"issue":"3","key":"2129_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000442671","volume":"55","author":"JP Marques","year":"2016","unstructured":"Marques JP, Costa JF, Marques M, Cachulo ML, Figueira J, Silva R. Sequential morphological changes in the CNV net after intravitreal anti-VEGF evaluated with OCT angiography. Ophthalmic Res. 2016;55(3):145\u201351.","journal-title":"Ophthalmic Res"},{"issue":"11","key":"2129_CR3","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1097\/IAE.0000000000000879","volume":"35","author":"B Lumbroso","year":"2015","unstructured":"Lumbroso B, Rispoli M, Savastano MC. Longitudinal optical coherence tomography-angiography study of type 2 naive choroidal neovascularization early response after treatment. Retina. 2015;35(11):2242\u201351.","journal-title":"Retina"},{"issue":"11","key":"2129_CR4","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1097\/IAE.0000000000000846","volume":"35","author":"D Huang","year":"2015","unstructured":"Huang D, Jia Y, Rispoli M, Tan O, Lumbroso B. Optical coherence tomography angiography of time course of choroidal neovascularization in response to anti-angiogenic treatment. Retina. 2015;35(11):2260\u20134.","journal-title":"Retina"},{"issue":"6","key":"2129_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.5301\/ejo.5000189","volume":"22","author":"G Coscas","year":"2012","unstructured":"Coscas G, Zhou Q, Coscas F, et al. Choroid thickness measurement with RTVue optical coherence tomography in emmetropic eyes, mildly myopic eyes, and highly myopic eyes. Eur J Ophthalmol. 2012;22(6):992\u20131000.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"2129_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1350-9462(98)00037-8","volume":"18","author":"A Harris","year":"1999","unstructured":"Harris A, Chung HS, Ciulla TA, Kagemann L. Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. Prog Retin Eye Res. 1999;18(5):669\u201387.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"2129_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0002-9394(99)00061-6","volume":"128","author":"TA Ciulla","year":"1999","unstructured":"Ciulla TA, Harris A, Chung HS, et al. Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration. Am J Ophthalmol. 1999;128(1):75\u201380.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2129_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ajo.2011.03.008","volume":"152","author":"V Manjunath","year":"2011","unstructured":"Manjunath V, Goren J, Fujimoto JG, Duker JS. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol. 2011;152(4):663\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2129_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s11357-019-00138-3","volume":"41","author":"A Lipecz","year":"2019","unstructured":"Lipecz A, Miller L, Kovacs I, et al. Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. GeroScience. 2019;41(6):813\u201345.","journal-title":"GeroScience"},{"issue":"4","key":"2129_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(4):627-633.e1.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"2129_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-306636","volume":"99","author":"K Mazaraki","year":"2015","unstructured":"Mazaraki K, Fassnacht-Riederle H, Blum R, Becker M, Michels S. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration. Br J Ophthalmol. 2015;99(10):1341\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"2129_CR12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00417-015-3260-3","volume":"254","author":"C Yun","year":"2016","unstructured":"Yun C, Oh J, Ahn J, et al. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1693\u2013702.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2129_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/jop.2014.0160","volume":"31","author":"M Gharbiya","year":"2015","unstructured":"Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V. Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther. 2015;31(6):357\u201362.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"2129_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/cxo.12877","volume":"102","author":"A SariyevaIsmay\u0131lov","year":"2019","unstructured":"Sariyeva Ismay\u0131lov A, Esen E, S\u0131zmaz S, Demircan AN. Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness. Clin Exp Optom. 2019;102(6):617\u201320.","journal-title":"Clin Exp Optom"},{"issue":"4","key":"2129_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00417-020-04957-5","volume":"259","author":"M Pellegrini","year":"2021","unstructured":"Pellegrini M, Bernabei F, Mercanti A, et al. Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2021;259(4):911\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"2129_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology. 2016;123(3):617\u201324.","journal-title":"Ophthalmology"},{"issue":"1","key":"2129_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12886-020-01542-6","volume":"20","author":"K Itagaki","year":"2020","unstructured":"Itagaki K, Sekiryu T, Kasai A, Sugano Y, Ogasawara M, Saito M. Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration. BMC Ophthalmol. 2020;20(1):276.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"2129_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10384-020-00783-8","volume":"65","author":"Y Tsunekawa","year":"2021","unstructured":"Tsunekawa Y, Kataoka K, Asai K, Ito Y, Terasaki H. Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration. Jpn J Ophthalmol. 2021;65(1):69\u201376.","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"2129_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.oret.2020.03.010","volume":"4","author":"I Maruko","year":"2020","unstructured":"Maruko I, Ogasawara M, Yamamoto A, et al. Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study. Ophthalmol Retina. 2020;4(8):767\u201376.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"2129_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.oret.2017.09.002","volume":"2","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Morimoto M, Mimura K, Ito A, Akiyama H. Treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration: efficacy and macular atrophy development. Ophthalmol Retina. 2018;2(5):462\u20138.","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"2129_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000479937","volume":"238","author":"A Ito","year":"2017","unstructured":"Ito A, Matsumoto H, Morimoto M, Mimura K, Akiyama H. Two-year outcomes of a treat-and-extend regimen using intravitreal aflibercept injections for typical age-related macular degeneration. Ophthalmologica. 2017;238(4):236\u201342.","journal-title":"Ophthalmologica"},{"issue":"4","key":"2129_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000189797","volume":"46","author":"W Schierling","year":"2009","unstructured":"Schierling W, Troidl K, Troidl C, Schmitz-Rixen T, Schaper W, Eitenm\u00fcller IK. The role of angiogenic growth factors in arteriogenesis. J Vasc Res. 2009;46(4):365\u201374.","journal-title":"J Vasc Res"},{"issue":"7","key":"2129_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jfo.2018.01.005","volume":"41","author":"A Barakat","year":"2018","unstructured":"Barakat A, Rufin V, Tran THC. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept. J Fr Ophtalmol. 2018;41(7):603\u201310.","journal-title":"J Fr Ophtalmol"},{"issue":"7","key":"2129_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/bjophthalmol-2018-312625","volume":"103","author":"JB Kumar","year":"2019","unstructured":"Kumar JB, Wai KM, Ehlers JP, Singh RP, Rachitskaya AV. Subfoveal choroidal thickness as a prognostic factor in exudative age-related macular degeneration. Br J Ophthalmol. 2019;103(7):918\u201321.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2129_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40259-016-0179-0","volume":"30","author":"AM Minnella","year":"2016","unstructured":"Minnella AM, Federici M, Falsini B, et al. Choroidal thickness changes after intravitreal ranibizumab for exudative age-related macular degeneration. BioDrugs. 2016;30(4):353\u20139.","journal-title":"BioDrugs"},{"issue":"8","key":"2129_CR26","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology. 2012;119(8):1621\u20137.","journal-title":"Ophthalmology"},{"issue":"8","key":"2129_CR27","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1097\/IAE.0000000000000122","volume":"34","author":"X-S Cao","year":"2014","unstructured":"Cao X-S, Peng X-Y, You Q-S, Zhang Y-P, Jonas JB. Subfoveal choroidal thickness change after intravitreal ranibizumab for idiopathic choroidal neovascularization. Retina. 2014;34(8):1554\u20139.","journal-title":"Retina"},{"issue":"5","key":"2129_CR28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ajo.2015.08.009","volume":"160","author":"S Razavi","year":"2015","unstructured":"Razavi S, Souied EH, Darvizeh F, Querques G. Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2015;160(5):1006\u201313.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"2129_CR29","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jfo.2017.04.014","volume":"40","author":"F Kaya","year":"2017","unstructured":"Kaya F. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: ranibizumab versus aflibercept. J Fr Ophtalmol. 2017;40(10):832\u20138.","journal-title":"J Fr Ophtalmol"},{"issue":"6","key":"2129_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.5301\/ejo.5000478","volume":"24","author":"S Sizmaz","year":"2014","unstructured":"Sizmaz S, Kucukerdonmez C, Kal A, Pinarci EY, Canan H, Yilmaz G. Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab. Eur J Ophthalmol. 2014;24(6):904\u201310.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"2129_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10792-016-0242-3","volume":"37","author":"C \u00dcnl\u00fc","year":"2017","unstructured":"\u00dcnl\u00fc C, Erdogan G, Gunay BO, Kardes E, Akcay BIS, Ergin A. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema. Int Ophthalmol. 2017;37(1):147\u201358.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"2129_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","volume":"127","author":"MC Gillies","year":"2020","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, et al. Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology. 2020;127(2):198\u2013210.","journal-title":"Ophthalmology"},{"issue":"12","key":"2129_CR33","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","volume":"127","author":"KL Spooner","year":"2020","unstructured":"Spooner KL, Fraser-Bell S, Cozzi M, et al. Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with vascular endothelial growth factor inhibitors using a treat-and-extend or a pro re nata regimen: four-year results of the MANEX study. Ophthalmology. 2020;127(12):1663\u201373.","journal-title":"Ophthalmology"},{"issue":"1","key":"2129_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/eye.2016.208","volume":"31","author":"M Gemenetzi","year":"2017","unstructured":"Gemenetzi M, Lotery AJ, Patel PJ. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye. 2017;31(1):1\u20139.","journal-title":"Eye"},{"issue":"8","key":"2129_CR35","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/bjophthalmol-2019-315055","volume":"104","author":"V Daien","year":"2020","unstructured":"Daien V, Nguyen V, Essex RW, et al. Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the fight retinal blindness! project. Br J Ophthalmol. 2020;104(8):1064\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"2129_CR36","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/aos.13157","volume":"94","author":"MR Munk","year":"2016","unstructured":"Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2016;94(8):e757\u201364.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2129_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150\u201361.","journal-title":"Ophthalmology"},{"issue":"4","key":"2129_CR38","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","volume":"122","author":"JE Grunwald","year":"2015","unstructured":"Grunwald JE, Pistilli M, Ying G-S, Maguire MG, Daniel E, Martin DF. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809\u201316.","journal-title":"Ophthalmology"},{"issue":"2","key":"2129_CR39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/jcm9020595","volume":"9","author":"C Iovino","year":"2020","unstructured":"Iovino C, Pellegrini M, Bernabei F, et al. Choroidal vascularity index: an in-depth analysis of this novel optical coherence tomography parameter. J Clin Med. 2020;9(2):595.","journal-title":"J Clin Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02129-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02129-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02129-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:25:08Z","timestamp":1662441908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02129-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02129-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}